
Erlotinib EURTAC



Erlotinib EURTAC Erlotinib EURTAC PRELIMINARY SCORE **CURATIVE NON-CURATIVE ADJUSTMENTS** Quality of life Not qualified for an ESMO-MCBS credit Serious and disabling adverse effects Less serious and disabling adverse events observed Other adjustments





© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.